RU2004105962A - Модель инфицирования mycoplasma bovis, способы введения m. bovis и способы индуцирования пневмонических повреждений легких - Google Patents

Модель инфицирования mycoplasma bovis, способы введения m. bovis и способы индуцирования пневмонических повреждений легких Download PDF

Info

Publication number
RU2004105962A
RU2004105962A RU2004105962/13A RU2004105962A RU2004105962A RU 2004105962 A RU2004105962 A RU 2004105962A RU 2004105962/13 A RU2004105962/13 A RU 2004105962/13A RU 2004105962 A RU2004105962 A RU 2004105962A RU 2004105962 A RU2004105962 A RU 2004105962A
Authority
RU
Russia
Prior art keywords
bovis
animal
specified
disease
culture
Prior art date
Application number
RU2004105962/13A
Other languages
English (en)
Inventor
Робин Ли КЕЙЧ (US)
Робин Ли КЕЙЧ
Ласло Паль ШТИПКОВИТШ (HU)
Ласло Паль ШТИПКОВИТШ
Original Assignee
Пфайзер Продактс Инк. (Us)
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. (Us), Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк. (Us)
Publication of RU2004105962A publication Critical patent/RU2004105962A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/101—Bovine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/30—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Claims (15)

1. Способ индуцирования у животного заболевания или нарушения, включающий введение эффективного количества культуры M. bovis и определение клинических симптомов указанного заболевания.
2. Способ по п.1, где указанное заболевание или нарушение выбрано из группы, состоящей из пневмонии, респираторных инфекций, легочных повреждений, артрита, мастита, отита, а также нарушений репродуктивных функций.
3. Способ по п.1, где указанное животное выбрано из группы, состоящей из кастрированных бычков, быков, коров и телят.
4. Способ по п.3, где указанным животным является корова.
5. Способ по п.3, где указанным животным является теленок.
6. Способ по п.1, где указанное эффективное количество культуры M. bovis включает приблизительно от 1х106 до 5х1011 колониеобразующих единиц (КОЕ) в инфицирующей дозе.
7. Способ по п.6, где указанное эффективное количество культуры M. bovis включает приблизительно от 1х108 до 1х1011 КОЕ/доза.
8. Способ по п.7, где указанное эффективное количество культуры M. bovis включает приблизительно от 1х1010 до 5х1010 КОЕ/доза.
9. Способ по п.1, где указанные клинические симптомы заболевания включают повышенные уровни M. bovis в легких, повышенную температуру или пониженный привес.
10. Способ по п.9, где указанной повышенной температурой является ректальная температура.
11. Способ оценки эффективности вакцины против M. bovis, включающий:
а. введение вакцины M. bovis первому животному;
b. заражение указанного животного эффективным количеством инфицирующей культуры M. bovis;
с. заражение второго животного эффективным количеством инфицирующей культуры M. bovis;
d определение клинических симптомов заболевания, вызванного указанным M. bovis; и
е. сравнение клинических симптомов заболевания, наблюдающихся у указанного первого животного с клиническими симптомами заболевания, наблюдающимися у указанного второго животного.
12. Способ по п.11, где указанная инфицирующая культура включает приблизительно от 1х106 до 5х1011 колониеобразующих единиц (КОЕ) в инфицирующей дозе.
13. Способ по п.12, где указанная инфицирующая культура включает приблизительно от 1х108 до 1х1011 КОЕ/доза.
14. Способ по п.13, где указанная инфицирующая культура включает приблизительно от 1х1010 до 5х1010 КОЕ/доза.
15. Способ по п.11, где указанные клинические симптомы заболевания включают повышенные уровни M. bovis в легких, повышенную температуру или пониженный привес.
RU2004105962/13A 2001-08-28 2002-07-25 Модель инфицирования mycoplasma bovis, способы введения m. bovis и способы индуцирования пневмонических повреждений легких RU2004105962A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31532401P 2001-08-28 2001-08-28
US60/315,324 2001-08-28

Publications (1)

Publication Number Publication Date
RU2004105962A true RU2004105962A (ru) 2005-03-27

Family

ID=23223885

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004105962/13A RU2004105962A (ru) 2001-08-28 2002-07-25 Модель инфицирования mycoplasma bovis, способы введения m. bovis и способы индуцирования пневмонических повреждений легких

Country Status (15)

Country Link
US (1) US20030180219A1 (ru)
EP (1) EP1420636A2 (ru)
JP (1) JP2005500845A (ru)
KR (1) KR20040031015A (ru)
CN (1) CN1571633A (ru)
AR (1) AR036355A1 (ru)
BR (1) BR0211563A (ru)
CA (1) CA2457514A1 (ru)
HU (1) HUP0401077A3 (ru)
IL (1) IL159145A0 (ru)
MX (1) MXPA04001872A (ru)
PL (1) PL368826A1 (ru)
RU (1) RU2004105962A (ru)
WO (1) WO2003017755A2 (ru)
ZA (1) ZA200309625B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121721A4 (en) * 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
AU2012258478B2 (en) * 2008-06-27 2013-10-03 Zoetis Services Llc Novel adjuvant compositions
CN104001170B (zh) 2008-06-27 2016-08-24 硕腾有限责任公司 新颖的佐剂组合物
CA2740954C (en) 2008-10-31 2018-09-25 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
PL2938747T3 (pl) 2012-12-28 2019-11-29 Boehringer Ingelheim Vetmedica Gmbh Sposób wytwarzania szczepionki przeciwko mykoplazmie
NZ733383A (en) 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
JP7113620B2 (ja) 2015-01-16 2022-08-05 ゾエティス・サービシーズ・エルエルシー 口蹄疫ワクチン
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN109833333A (zh) * 2019-02-16 2019-06-04 首都医科大学附属北京中医医院 一种制备肺炎大鼠模型的方法及模型评价方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149471A0 (en) * 1999-11-08 2002-11-10 Biomune Vaccines for mycoplasma bovis and methods for immunizing bovine amimals
JP2004537543A (ja) * 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法

Also Published As

Publication number Publication date
AR036355A1 (es) 2004-09-01
BR0211563A (pt) 2004-07-13
CA2457514A1 (en) 2003-03-06
KR20040031015A (ko) 2004-04-09
WO2003017755A2 (en) 2003-03-06
CN1571633A (zh) 2005-01-26
HUP0401077A2 (hu) 2004-08-30
JP2005500845A (ja) 2005-01-13
IL159145A0 (en) 2004-06-01
US20030180219A1 (en) 2003-09-25
PL368826A1 (en) 2005-04-04
ZA200309625B (en) 2004-12-13
HUP0401077A3 (en) 2004-10-28
WO2003017755A3 (en) 2003-10-23
EP1420636A2 (en) 2004-05-26
MXPA04001872A (es) 2004-06-15

Similar Documents

Publication Publication Date Title
Boileau et al. Bovine coronavirus associated syndromes
Callan et al. Biosecurity and bovine respiratory disease
Higgins et al. The Equine Manual E-Book: The Equine Manual E-Book
Lorenz et al. Calf health from birth to weaning. III. Housing and management of calf pneumonia
Mohamed et al. A review on pneumonic pasteurellosis (respiratory mannheimiosis) with emphasis on pathogenesis, virulence mechanisms and predisposing factors
Abubakar et al. Clinico‐pathological changes in buffalo calves following oral exposure to Pasteurella multocida B: 2
RU2004105962A (ru) Модель инфицирования mycoplasma bovis, способы введения m. bovis и способы индуцирования пневмонических повреждений легких
Rafidah et al. Efficacy of intranasal vaccination of field buffaloes against haemorrhagic septicaemia with a live gdhA derivative Pasteurella multocida B: 2
Valarcher et al. Viral respiratory infections in cattle.
Desrosiers A review of some aspects of the epidemiology, diagnosis, and control of Mycoplasma hyopneumoniae infections
Clavijo et al. Temporal patterns of colonization and infection with Mycoplasma hyorhinis in two swine production systems in the USA
Laber et al. Biology and diseases of swine
Habing et al. Efficacy of oral administration of a modified-live Salmonella Dublin vaccine in calves
Cutler et al. Antimicrobial prescribing guidelines for pigs
Myint et al. Safety, efficacy and cross‐protectivity of a live intranasal aerosol haemorrhagic septicaemia vaccine
Schmitt et al. Influence of ampicillin, ceftiofur, attenuated live PRRSV vaccine, and reduced dose Streptococcus suis exposure on disease associated with PRRSV and S. suis coinfection
Williams et al. Studies of the efficacy of a novel intranasal vaccine against feline bordetellosis
Ramirez Diseases affecting pigs: An overview of common bacterial, viral and parasitic pathogens of pigs
Woldehiwet et al. The effects of age, environmental temperature and relative humidity on the bacterial flora of the upper respiratory tract in calves
Bush Giraffidae
Rivas et al. Herpesvirus and calicivirus infection in a black-footed cat (Felis nigripes) family group following vaccination
Maillard et al. Respiratory disease in adult cattle.
Hoffmann et al. The effect of a homologous bacterin given to sows prefarrowing on the development of Glässer's disease in postweaning pigs after iv challenge with Haemophilus parasuis serotype 5.
Patel et al. Bovine respiratory disease complex: A critical review
Bonmarchand et al. Group R streptococci: wild boars as a second reservoir

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060309